Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma (MANDALA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03769090
Recruitment Status : Recruiting
First Posted : December 7, 2018
Last Update Posted : November 28, 2019
Sponsor:
Information provided by (Responsible Party):
Bond Avillion 2 Development LP

Brief Summary:
This is a randomized, double-blind, multicenter, parallel-group, variable-length study to compare 2 doses of BDA MDI (PT027) with AS MDI (PT007) on the time to first severe asthma exacerbation in adult, adolescent, and pediatric subjects with moderate to severe asthma.

Condition or disease Intervention/treatment Phase
Asthma Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg Combination Product: Albuterol sulfate metered-dose inhaler 180 μg Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 3100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Long-term, Randomized, Double-blind, Multicenter, Parallel-group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT007 Administered as Needed in Response to Symptoms in Symptomatic Adults and Children 4 Years of Age or Older With Asthma
Actual Study Start Date : December 27, 2018
Estimated Primary Completion Date : September 15, 2020
Estimated Study Completion Date : December 1, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Experimental: BDA MDI (PT027) 80/180 μg
BDA MDI (PT027) low dose
Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg
Budesonide/albuterol sulfate combination inhalation aerosol

Experimental: BDA MDI (PT027) 160/180 μg
BDA MDI (PT027) high dose
Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg
Budesonide/albuterol sulfate combination inhalation aerosol

Active Comparator: AS MDI (PT007) 90 µg Combination Product: Albuterol sulfate metered-dose inhaler 180 μg
Albuterol sulfate inhalation aerosol




Primary Outcome Measures :
  1. Time to first severe asthma exacerbation [ Time Frame: until 570 total first severe asthma exacerbation events have occurred and all subjects have been assessed for at least 24 weeks after starting treatment ]
    Time to first severe asthma exacerbation will be calculated as the time from randomization until the start date of the first severe asthma exacerbation. An asthma exacerbation will be considered severe if it results in at least 1 of the following: a temporary bolus/burst of systemic corticosteroids for at least 3 consecutive days to treat symptoms of asthma worsening (a single depo-injectable dose of corticosteroids will be considered equivalent), an emergency room or urgent care visit (< 24 hours in the facility for evaluation and treatment) due to asthma that required systemic corticosteroids, or an in-patient hospitalization (admission to an in-patient facility and/or ≥ 24 hours in a healthcare facility) due to asthma.


Secondary Outcome Measures :
  1. Severe exacerbation rate (annualized) [ Time Frame: until 570 total first severe asthma exacerbation events have occurred and all subjects have been assessed for at least 24 weeks after starting treatment ]
    The annualized exacerbation rate is based on exacerbations reported in the Asthma Exacerbation eCRF

  2. Total corticosteroid exposure over the treatment period [ Time Frame: until 570 total first severe asthma exacerbation events have occurred and all subjects have been assessed for at least 24 weeks after starting treatment ]
    Total corticosteroid exposure reported as the mean daily dose will be calculated for each subject as the sum of the cumulative doses of maintenance inhaled corticosteroids, reliever inhaled corticosteroids, prescribed inhaled corticosteroids, and systemic corticosteroids divided by the number of days the subject was in the study prior to treatment discontinuation.

  3. Asthma Control Questionnaire-5 (ACQ-5) change from baseline at Week 24 [ Time Frame: 24 weeks ]
    Change from baseline in ACQ-5 as compared to albuterol sulfate at Week 24. The ACQ-5 consists of 5 questions on symptom control, with each scored on a 7-point scale (0 = excellent asthma control; 6 = extremely poor control). The overall score (0 = excellent asthma control; 6 = extremely poor control) is the mean of the 5 symptom items.

  4. Asthma Control Questionnaire-5 (ACQ-5) responder analysis at Week 24 [ Time Frame: 24 weeks ]
    ACQ-5 responders as compared to albuterol sulfate at Week 24. ACQ-5 responders are defined as subjects achieving a decline from baseline of at least 0.5 on the ACQ-5.

  5. Asthma Quality of Life Questionnaire (AQLQ) for 12 years and older/Pediatric Asthma Quality of Life Questionnaire (PAQLQ) change from baseline at Week 24 [ Time Frame: 24 weeks ]
    AQLQ consists of 32 questions in 4 domains and PAQLQ consists of 23 questions in 3 domains. Both are assessed on separate 7-point Likert scales from 1 to 7, with higher values indicating better health-related quality of life. The overall score is the mean of all responses. As the PAQLQ is not validated for children less than 7 years of age, data for subjects who are aged 4 to 6 years will be excluded from the analyses of PAQLQ endpoints.

  6. Asthma Quality of Life Questionnaire (AQLQ) for 12 years and older/Pediatric Asthma Quality of Life Questionnaire (PAQLQ) responder analysis at Week 24 [ Time Frame: 24 weeks ]
    Responders at Week 24 are defined as subjects achieving an increase from baseline of at least 0.5 on the AQLQ or PAQLQ



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   4 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Female or male aged ≥4 years at the time of informed consent
  2. Physician diagnosis of asthma documented for at least 1 year
  3. Receiving 1 of the following scheduled asthma maintenance therapies for 3 months with stable dosing for at least the last 4 weeks before Visit 1:

    • Medium-to-high-dose inhaled corticosteroid (ICS)
    • Medium-to-high-dose ICS and 1 additional maintenance therapy from the following: leukotriene receptor antagonists (LTRA), long-acting muscarinic antagonists (LAMA), or theophylline
    • Low-to-high-dose ICS in combination with long-acting β2-adrenoreceptor agonist (LABA) with or without one additional maintenance therapy from the following: LTRA, LAMA, or theophylline
  4. Prebronchodilator forced expiratory volume in 1 second (FEV1) of ≥40 to <90% predicted normal value for adults and adolescents, and ≥60 to <100% predicted normal value for subjects aged 4 to 11 years after withholding specified medications including short/rapid-acting β2-adrenoreceptor agonist (SABA)
  5. Demonstrate reversibility at Visit 1, with an increase in FEV1 ≥12% (and ≥200 mL for subjects aged ≥18 years) relative to baseline after administration of sponsor provided Ventolin via central spirometry. One re-test for reversibility testing is allowed within the screening period in advance of Visit 2
  6. Demonstrate acceptable spirometry performance (i.e., meet American Thoracic Society/European Respiratory Society acceptability/repeatability criteria)
  7. A documented history of at least 1 severe asthma exacerbation within 12 months before Visit 1
  8. Able to perform acceptable and reproducible peak expiratory flow (PEF) measurements as assessed by the investigator

Exclusion Criteria:

  1. Chronic obstructive pulmonary disease or other significant lung disease (e.g., chronic bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis, or bronchopulmonary dysplasia)
  2. Oral corticosteroid/SCS use (any dose and any indication) within 6 weeks before Visit 1
  3. Chronic use of oral corticosteroids (OCS, ≥3 weeks use in 3 months prior to Visit 1)
  4. Having received any marketed (e.g., omalizumab, mepolizumab, reslizumab, benralizumab) or investigational biologic within 3 months or any other prohibited medication
  5. Current smokers, former smokers with >10 pack-years history, or former smokers who stopped smoking <6 months before Visit 1 (including all forms of tobacco, e-cigarettes [vaping], and marijuana)
  6. Life-threatening asthma defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma related syncopal episode(s) within 5 years of Visit 1
  7. Historical or current evidence of a clinically significant disease
  8. Cancer not in complete remission for at least 5 years
  9. Hospitalization for psychiatric disorder or attempted suicide within 1 year of Visit 1
  10. History of psychiatric disease, intellectual deficiency, poor motivation, or other conditions if their magnitude is limiting informed consent validity
  11. Significant abuse of alcohol or drugs

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03769090


Contacts
Layout table for location contacts
Contact: Piotr Bernat, PharmD 48 22 219 5184 piotr.bernat@syneoshealth.com

  Hide Study Locations
Locations
Layout table for location information
United States, Alabama
Research Site Recruiting
Birmingham, Alabama, United States, 35209
Research Site Recruiting
Huntsville, Alabama, United States, 35801
Research Site Recruiting
Mobile, Alabama, United States, 36608
Research Site Recruiting
Montgomery, Alabama, United States, 36106
Research Site Recruiting
Sheffield, Alabama, United States, 35660
United States, Arizona
Research Site Recruiting
Glendale, Arizona, United States, 85306
Research Site Recruiting
Peoria, Arizona, United States, 85381
Research Site Recruiting
Scottsdale, Arizona, United States, 85251
United States, Arkansas
Research Site Recruiting
Little Rock, Arkansas, United States, 72209
United States, California
Research Site Recruiting
Bellflower, California, United States, 90706
Research Site Recruiting
Encinitas, California, United States, 92024
Research Site Recruiting
Long Beach, California, United States, 90806
Research Site Recruiting
Los Angeles, California, United States, 90017
Research Site Recruiting
Newport Beach, California, United States, 92663
Research Site Recruiting
Palmdale, California, United States, 93551
Research Site Recruiting
Rancho Cucamonga, California, United States, 91730
Research Site Recruiting
Redwood City, California, United States, 94063
Research Site Recruiting
Sacramento, California, United States, 95823
Research Site Recruiting
San Francisco, California, United States, 94102
Research Site Recruiting
Westminster, California, United States, 92683
United States, Colorado
Research Site Recruiting
Colorado Springs, Colorado, United States, 80909
Research Site Recruiting
Denver, Colorado, United States, 80246
United States, Connecticut
Research Site Recruiting
Waterbury, Connecticut, United States, 06708
United States, Florida
Research Site Recruiting
Aventura, Florida, United States, 33180
Research Site Recruiting
Boynton Beach, Florida, United States, 33436
Research Site Recruiting
Clearwater, Florida, United States, 33756
Research Site Recruiting
Clearwater, Florida, United States, 33765
Research Site Recruiting
DeLand, Florida, United States, 32720
Research Site Recruiting
Gainesville, Florida, United States, 32653
Research Site Recruiting
Green Acres, Florida, United States, 33467
Research Site Recruiting
Hialeah, Florida, United States, 33012
Research Site Recruiting
Kissimmee, Florida, United States, 34741
Research Site Recruiting
Miami, Florida, United States, 33125
Research Site Recruiting
Miami, Florida, United States, 33126
Research Site Recruiting
Miami, Florida, United States, 33135
Research Site Recruiting
Miami, Florida, United States, 33144
Research Site Recruiting
Miami, Florida, United States, 33173
Research Site Recruiting
Miami, Florida, United States, 33174
Research Site Recruiting
Miami, Florida, United States, 33175
Research Site Recruiting
Miami, Florida, United States, 33186
Research Site Recruiting
Orlando, Florida, United States, 32806
Research Site Recruiting
Orlando, Florida, United States, 32819
Research Site Recruiting
Palmetto Bay, Florida, United States, 33157
Research Site Recruiting
Panama City, Florida, United States, 32405
Research Site Recruiting
Pembroke Pines, Florida, United States, 33024
Research Site Recruiting
Pembroke Pines, Florida, United States, 33026
Research Site Recruiting
Saint Petersburg, Florida, United States, 33707
Research Site Recruiting
Saint Petersburg, Florida, United States, 33710
United States, Idaho
Research Site Recruiting
Meridian, Idaho, United States, 83646
United States, Iowa
Research Site Recruiting
Iowa City, Iowa, United States, 52242
United States, Kansas
Research Site Recruiting
Overland Park, Kansas, United States, 66210
United States, Kentucky
Research Site Recruiting
Owensboro, Kentucky, United States, 42301
United States, Maine
Research Site Recruiting
Bangor, Maine, United States, 04401
United States, Maryland
Research Site Recruiting
Chevy Chase, Maryland, United States, 20815
Research Site Recruiting
White Marsh, Maryland, United States, 21162
United States, Massachusetts
Research Site Recruiting
Boston, Massachusetts, United States, 02115
Research Site Recruiting
Fall River, Massachusetts, United States, 02723
Research Site Recruiting
North Dartmouth, Massachusetts, United States, 02747
United States, Michigan
Research Site Recruiting
Ann Arbor, Michigan, United States, 48109
Research Site Recruiting
Farmington Hills, Michigan, United States, 48336
Research Site Recruiting
Flint, Michigan, United States, 48504
Research Site Recruiting
Hamtramck, Michigan, United States, 48212
Research Site Recruiting
Ypsilanti, Michigan, United States, 48197
United States, Missouri
Research Site Recruiting
Hazelwood, Missouri, United States, 63042
Research Site Recruiting
Saint Louis, Missouri, United States, 63141
United States, Nebraska
Research Site Recruiting
Bellevue, Nebraska, United States, 68005
Research Site Recruiting
Lincoln, Nebraska, United States, 68505
United States, New Jersey
Research Site Recruiting
Brick, New Jersey, United States, 08724
Research Site Recruiting
Marlton, New Jersey, United States, 08053
Research Site Recruiting
Toms River, New Jersey, United States, 08755
United States, New Mexico
Research Site Recruiting
Albuquerque, New Mexico, United States, 87131
United States, New York
Research Site Recruiting
Bronx, New York, United States, 10461
Research Site Recruiting
Brooklyn, New York, United States, 11230
Research Site Recruiting
New Hyde Park, New York, United States, 11040
Research Site Recruiting
Potsdam, New York, United States, 13676
United States, North Carolina
Research Site Recruiting
Asheville, North Carolina, United States, 28801
Research Site Recruiting
Charlotte, North Carolina, United States, 28207
Research Site Recruiting
Charlotte, North Carolina, United States, 28210
Research Site Recruiting
Charlotte, North Carolina, United States, 28277
Research Site Recruiting
Gastonia, North Carolina, United States, 28054
Research Site Recruiting
High Point, North Carolina, United States, 27262
Research Site Recruiting
Monroe, North Carolina, United States, 28112
Research Site Recruiting
Winston-Salem, North Carolina, United States, 27104
United States, North Dakota
Research Site Recruiting
Fargo, North Dakota, United States, 58104
United States, Ohio
Research Site Recruiting
Cincinnati, Ohio, United States, 45231
Research Site Recruiting
Cincinnati, Ohio, United States, 45242
Research Site Recruiting
Columbus, Ohio, United States, 43207
Research Site Recruiting
Dayton, Ohio, United States, 45406
Research Site Recruiting
Dublin, Ohio, United States, 43016
United States, Oklahoma
Research Site Recruiting
Edmond, Oklahoma, United States, 73034
Research Site Recruiting
Oklahoma City, Oklahoma, United States, 73112
United States, Oregon
Research Site Recruiting
Medford, Oregon, United States, 97504
United States, Pennsylvania
Research Site Recruiting
Blue Bell, Pennsylvania, United States, 19422
Research Site Recruiting
Erie, Pennsylvania, United States, 16508
Research Site Recruiting
Pittsburgh, Pennsylvania, United States, 15241
United States, Rhode Island
Research Site Recruiting
Providence, Rhode Island, United States, 02908
Research Site Recruiting
Warwick, Rhode Island, United States, 02886
United States, South Carolina
Research Site Recruiting
Clinton, South Carolina, United States, 29325
Research Site Recruiting
Gaffney, South Carolina, United States, 29341
Research Site Recruiting
Mount Pleasant, South Carolina, United States, 29464
Research Site Recruiting
Myrtle Beach, South Carolina, United States, 29588
Research Site Recruiting
Rock Hill, South Carolina, United States, 29732
Research Site Recruiting
Spartanburg, South Carolina, United States, 29303
United States, Texas
Research Site Recruiting
Austin, Texas, United States, 78726
Research Site Recruiting
Austin, Texas, United States, 78759
Research Site Recruiting
Beaumont, Texas, United States, 77702
Research Site Recruiting
Boerne, Texas, United States, 78006
Research Site Recruiting
Corsicana, Texas, United States, 75110
Research Site Recruiting
Dallas, Texas, United States, 75225
Research Site Recruiting
Galveston, Texas, United States, 77555
Research Site Recruiting
Kerrville, Texas, United States, 78028
Research Site Recruiting
Live Oak, Texas, United States, 78233
Research Site Recruiting
McKinney, Texas, United States, 75069
Research Site Recruiting
Pearland, Texas, United States, 77584
Research Site Recruiting
San Antonio, Texas, United States, 78229
Research Site Recruiting
San Antonio, Texas, United States, 78230
Research Site Recruiting
Sherman, Texas, United States, 75092
Research Site Recruiting
Tomball, Texas, United States, 77375
Research Site Recruiting
Waco, Texas, United States, 76712
Research Site Recruiting
Waxahachie, Texas, United States, 75165
United States, Utah
Research Site Recruiting
Murray, Utah, United States, 84107
United States, Vermont
Research Site Recruiting
South Burlington, Vermont, United States, 05403
United States, West Virginia
Research Site Recruiting
Morgantown, West Virginia, United States, 26505
United States, Wisconsin
Research Site Recruiting
Greenfield, Wisconsin, United States, 53228
Argentina
Research Site Recruiting
Caba, Argentina
Research Site Recruiting
Lanús, Argentina
Research Site Recruiting
Mar Del Plata, Argentina
Research Site Recruiting
Rosario, Argentina
Research Site Recruiting
San Fernando, Argentina
Research Site Recruiting
San Miguel De Tucumán, Argentina
Canada, Ontario
Research Site Recruiting
Ajax, Ontario, Canada, L1S 2J5
Research Site Recruiting
Burlington, Ontario, Canada, L7N 3V2
Research Site Recruiting
Sarnia, Ontario, Canada, N7T 4X3
Research Site Recruiting
Sudbury, Ontario, Canada, P3A 1W8
Research Site Recruiting
Toronto, Ontario, Canada, M9V 4B4
Canada, Quebec
Research Site Recruiting
Québec, Quebec, Canada, C1G 3Y8
Canada
Rosenheim Recruiting
Vancouver, Canada
Czechia
Research Site Recruiting
Brandýs Nad Labem, Czechia
Research Site Recruiting
Kralupy Nad Vltavou, Czechia
Research Site Recruiting
Praha, Czechia
Germany
Research Site Recruiting
Rosenheim, Germany
Spain
Research Site Recruiting
Barcelona, Spain
Research Site Recruiting
Girona, Spain
United Kingdom
Research Site Recruiting
Blackpool, United Kingdom
Research Site Recruiting
Chippenham, United Kingdom
Research Site Recruiting
Liverpool, United Kingdom
Research Site Recruiting
London, United Kingdom
Research Site Recruiting
Northwood, United Kingdom
Research Site Recruiting
Nottingham, United Kingdom
Research Site Recruiting
Romford, United Kingdom
Research Site Recruiting
Sidcup, United Kingdom
Sponsors and Collaborators
Bond Avillion 2 Development LP

Layout table for additonal information
Responsible Party: Bond Avillion 2 Development LP
ClinicalTrials.gov Identifier: NCT03769090     History of Changes
Other Study ID Numbers: AV003
First Posted: December 7, 2018    Key Record Dates
Last Update Posted: November 28, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Budesonide
Albuterol
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action